EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19

Han Yan, Shanbiao Hu, Hedong Zhang, Yangang Zhou, Rao Fu, Ping Xu, Hualin Cai, Xi Li, Gongbin Lan iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0309875 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Han Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Immunosuppressive Agents, Kidney Transplantation, Ritonavir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplantation recipients (KTRs) represent a vulnerable population for COVID-19 infection and severe disease. Nirmatrelvir-ritonavir has demonstrated efficacy in treating COVID-19 among KTRs, and interacts with tacrolimus leading to a precipitous increase in tacrolimus blood levels when co-administered, which may potentially result in toxicity. To explore a safe strategy for the combination of nirmatrelvir-ritonavir and tacrolimus, we established a new administration strategy to restore tacrolimus after the discontinuation of nirmatrelvir-ritonavir and conducted a real-world retrospective observational cohort study to evaluate its clinical efficacy. In the experimental group, tacrolimus was initiated at 20–25% of the baseline dose 48 hours after the discontinuation of nirmatrelvir-ritonavir, with daily increments of 20–25% until the baseline dose was restored. The patients who did not follow the experimental protocol were included in the control group. Results showed that withholding tacrolimus 12 hours before starting nirmatrelvir-ritonavir maintained tacrolimus blood levels above 83% of the baseline throughout the nirmatrelvir-ritonavir treatment period. Compared with the control group, the experimental group achieved target trough concentrations of tacrolimus more quickly and maintained a higher proportion within the therapeutic range ( p = 0.029), and had significantly lower rates of adverse events ( p = 0.002, OR = 0.308, 95%CI:0.136–0.695). This study provides a safe and effective pharmacological strategy for KTRs infected with COVID-19, allowing the safe co-administration of nirmatrelvir-ritonavir and tacrolimus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentImmunosuppressive AgentsKidney TransplantationRitonavirTacrolimusAdultAgedFemaleHumansMaleMiddle AgedCOVID-19Drug Therapy, CombinationRetrospective StudiesSARS-CoV-2Transplant Recipients

Substanzen

Immunosuppressive AgentsRitonavirTacrolimus

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
  • Institute of Clinical Pharmacy, Central South University, Changsha, China.
  • Department of Kidney Transplantation, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
  • Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan, P.R. China.

ORCID-Profile: Gongbin Lan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Yan, H., Hu, S., Zhang, H., Zhou, Y., Fu, R., Xu, P., Cai, H., Li, X., & Lan, G. (2025). Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. PLOS One. https://doi.org/10.1371/journal.pone.0309875

Vancouver

Yan H, Hu S, Zhang H, Zhou Y, Fu R, Xu P, et al. Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. PLOS One. 2025. doi:10.1371/journal.pone.0309875

BibTeX
@article{Yan2025,
  author = {Yan, Han and Hu, Shanbiao and Zhang, Hedong and Zhou, Yangang and Fu, Rao and Xu, Ping and Cai, Hualin and Li, Xi and Lan, Gongbin},
  title = {Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0309875}
}
Kostenlos starten →